With the advent of more effective pharmacotherapy for obesity, particularly glucagon-like peptide (GLP-1) agonists and dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) agonists, questions have been raised about the role of surgery in the future treatment of obesity [31]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.